These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20682400)
1. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate. Kubota Y; Waki M Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400 [No Abstract] [Full Text] [Related]
2. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase. Zámecníkova A; Al Bahar S; Ramesh P Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829 [TBL] [Abstract][Full Text] [Related]
3. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391 [TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2). Takeuchi M; Katayama Y; Okamura A; Yamamoto K; Shimoyama M; Matsui T Cancer Genet Cytogenet; 2007 Nov; 179(1):85-7. PubMed ID: 17981222 [No Abstract] [Full Text] [Related]
5. A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia. Vaidya S; Joshi D; Ghosh K; Chakrabarti P; Vundinti BR Hum Pathol; 2013 Oct; 44(10):2365-9. PubMed ID: 23759653 [TBL] [Abstract][Full Text] [Related]
6. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867 [TBL] [Abstract][Full Text] [Related]
7. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128 [TBL] [Abstract][Full Text] [Related]
8. New tyrosine kinase inhibitors in chronic myeloid leukemia. Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950 [TBL] [Abstract][Full Text] [Related]
9. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia. Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303 [TBL] [Abstract][Full Text] [Related]
11. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia. Arancibia AM; Bendit I; Epelman S Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674 [No Abstract] [Full Text] [Related]
12. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671 [No Abstract] [Full Text] [Related]
13. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498 [TBL] [Abstract][Full Text] [Related]
14. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases. Tunca Y; Güran S Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207 [No Abstract] [Full Text] [Related]
15. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia. Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138 [No Abstract] [Full Text] [Related]
16. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431 [TBL] [Abstract][Full Text] [Related]
17. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia. Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234 [No Abstract] [Full Text] [Related]
18. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300 [TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. Snyder DS; McMahon R; Cohen SR; Slovak ML Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375 [TBL] [Abstract][Full Text] [Related]
20. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response. Cariani E; Capucci M; Micheletti M; Spalenza F; Zanella I; Albertini A; Rossi G Ann Hematol; 2003 Jun; 82(6):333-5. PubMed ID: 12734675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]